

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Veginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/888,164	06/22/2001	Paul O.P. Ts'o	212241	9080
	590 06/11/2003			
LEYDIG VOIT & MAYER, LTD TWO PRUDENTIAL PLAZA, SUITE 4900			EXAMINER	
180 NORTH STETSON AVENUE CHICAGO, IL 60601-6780		00	SCHMIDT, MARY M	
	00001 0700		ART UNIT	PAPER NUMBER
			1635	9
			DATE MAILED: 06/11/2003	,

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
· Office Action Summary		09/888,164	TS'O ET AL.			
		Examiner	Art Unit			
		Mary M. Schmidt	1635			
Period fo	The MAILING DATE of this communication aper r Reply	ppears on the cover sheet wit	th the correspondence address			
- Exter after - If the - If NO - Failur - Any re	ORTENED STATUTORY PERIOD FOR REP MAILING DATE OF THIS COMMUNICATION isions of time may be available under the provisions of 37 CFR 1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reperiod for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statually received by the Office later than three months after the mailing dipatent term adjustment. See 37 CFR 1.704(b).	. 136(a). In no event, however, may a re ply within the statutory minimum of thirty d will apply and will expire SIX (6) MONT	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication.			
1)	Responsive to communication(s) filed on					
2a) <u></u> □		his action is non-final.				
3) Disposition	Since this application is in condition for allow closed in accordance with the practice under on of Claims	/ance except for formal matte	ers, prosecution as to the merits is . 11, 453 O.G. 213.			
4)⊠	Claim(s) $1-71$ is/are pending in the applicatio	n.				
4	4a) Of the above claim(s) is/are withdrawn from consideration.					
	Claim(s) is/are allowed.					
6)□ (	Claim(s) is/are rejected.					
7) 🗌 (	Claim(s) is/are objected to.					
8)⊠ ( Applicatio	Claim(s) <u>1-71</u> are subject to restriction and/or n Papers	election requirement.				
9)∐ T	he specification is objected to by the Examine	er .				
	ne drawing(s) filed on is/are: a)□ acce		Evening			
	Applicant may not request that any objection to the	e drawing(s) he held in abeyon	CO. Soc 27 CER 4 RE(-)			
11)[] Th	ne proposed drawing correction filed on	is: a) ☐ approved b) ☐ disa	annroyed by the Evenine			
	If approved, corrected drawings are required in re	ply to this Office action	approved by the Examiner.			
12)∐ Tr	ne oath or declaration is objected to by the Ex	aminer.				
	der 35 U.S.C. §§ 119 and 120					
		n priority under 35 H.S.C. & 1	19(a) (d) or (f)			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
	Copies of the certified copies of the prior application from the International Bure the attached detailed Office action for a list of the action f	ity documents have been rec	ceived in this National Stage			
14)∐ Ack	nowledgment is made of a claim for domestic	or the definied copies flot fet	40(-) (t-			
a) L	The translation of the foreign language provinced in the stranslation of the foreign language provinced in the stranslation of	visional application has been	received			
ttachment(s)	g	s priority under 35 U.S.C. §§	120 and/or 121.			
Notice of	f References Cited (PTO-892) f Draftsperson's Patent Drawing Review (PTO-948) on Disclosure Statement(s) (PTO-1449) Paper No(s)		mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)			
O-326 (Rev. 0	4.043	ion Summary	Part of Paper No. 9			

Art Unit: 1635

## **DETAILED ACTION**

## Election/Restriction

1. The following restriction is required for the individual sequences of claims 17, 69 and 71.

Pursuant to 35 U.S.C. 121 and 37 C.F.R. 1.141, the oligonucleotide sequences listed in claims 17, 69 and 71 are subject to restriction. The Commissioner has partially waived the requirements of 37 C.F.R. 1.141 and will permit a reasonable number of such nucleotide sequences to be claimed in a single application. Under this policy, up to 10 of independent and distinct nucleotide sequences will be examined in a single application. (see MPEP 803.04 and 2434).

Claims 17, 69 and 71 specifically claim the following three oligonucleotides:

GTTCTCCATGTTCAG, TTTATAAGGGTCGATGTCCAT, and AAAGCCACCCAAGGCA.

Although these oligonucleotide sequences each are useful in the claimed A-L-P constructs as oligomers that bind a pathogen, the instant antisense sequences are considered to be unrelated,
since each sequence claimed is structurally and functionally independent and distinct for the
following reasons: each sequence has a unique nucleotide sequence, each antisense sequence
targets a different and specific region of a pathogen, and each sequence, upon binding to the
pathogen, functionally modulates (increases or decreases) the pathogen to a varying degree.

Furthermore, a search of more than one (1) of the oligonucleotide sequences claimed in claims
17, 69 and 71 presents an undue burden on the Patent and Trademark Office due to the complex

Application/Control Number: 09/888,164 Page 3

Art Unit: 1635

nature of the search and corresponding examination of more than one (1) of the claimed sequences. In view of the foregoing, one (1) sequence is considered to be a reasonable number of sequences for examination. Accordingly, applicants are required to elect one (1) sequence from claims 17, 69 and 71.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 2. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).
- 3. The following restriction is also required: This application contains claims directed to the following patentably distinct species of the claimed invention: (1) a hepatic ligand that binds a specific hepatic receptor, part A of the A-L-P construct; (2) a linker that links A and P in the A-L-P construct; (3) a specific oligomer target that the oligomer binds.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable for each of groups (1), (2) and (3) above. Currently, claims 1 and 64 are generic

Application/Control Number: 09/888,164 Page 4

Art Unit: 1635

to all groups. Claims 1, 30-36 and 64, a ligand and linker must be chosen. Claims 1-29 and 64-71, one oligomer and/or oligomer target must be chosen.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/888,164

Page 5

Art Unit: 1635

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

6. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Mary M. Schmidt, whose telephone number is (703) 308-4471.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, John LeGuyader, may be reached at (703) 308-0447.

Inquiries relating to the status of this application may also be directed to Katrina Turner,

whose telephone number is (703) 305-3413.

JOHN L. LEGUYADER
ERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600

M. M. Schmidt June 9, 2003